Skip to main content

Table 5 Baseline demographics and clinical characteristics, including CV risk factors for the CHF analysis (of investigator-reported events)

From: Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events

  Linagliptin (n = 5488) Placebo (n = 3290)
Gender, % of patients Male/female 53.5/46.5 54.9/45.1
Age, years 58.2 ± 10.6 58.1 ± 10.6
BMI, kg/m2 29.3 ± 5.3 30.0 ± 5.4
Race, % of patients
White 59.5 63.0
Black 4.3 7.4
Asian 36.2 29.6
HbA1c, mmol/mol 66.1 ± 9.8 66.1 ± 9.8
HbA1c, % 8.2 ± 0.9 8.2 ± 0.9
FPG, mg/dL 166.2 ± 45.7 168.2 ± 47.4
Diabetes duration, % of patients
≤1 year 15.4 15.8
1–5 years 30.6 30.3
>5 years 53.9 53.7
Missing 0.1 0.2
Antidiabetes drugs at enrolment, % of patients
None 21.7 25.6
1 38.9 39.1
2 38.1 33.5
≥3 1.2 1.7
  1. BMI, body mass index; CHF, congestive heart failure; CV, cardiovascular; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; MDRD, Modification of Diet in Renal Disease.
  2. Values are mean ± SD, unless otherwise stated.